ARROWHEAD PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of -$4.17 million for the 12-month period ending 2010-09-30, per its 10-Q filed 2014-05-06.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2014-05-06
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month |
|---|---|
| 2010-09-30 | -$4.17M 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |